1010446-31-7

Basic information

• Product Name: (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate;(3S)-3-(1-Piperazinyl)-1-pyrrolidinecarboxylic acid tert-butyl ester
• CAS NO: 1010446-31-7
• Molecular Formula: C13H25N3O2
• Molecular Weight: 255.3565
• Mol File: 1010446-31-7.mol

Chemical Properties

• Appearance: /
• Density: 1.090
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate(1010446-31-7)
• EPA Substance Registry System: (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate(1010446-31-7)

Safety Data

• Hazardous Substances Data: 1010446-31-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
(S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate is utilized as a chemical intermediate for the synthesis of various pharmaceutical agents. Its unique structure and pharmacological properties make it a valuable component in the development of new drugs targeting specific biological pathways.
Used in Drug Discovery and Development:
In the field of drug discovery and development, (S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate serves as a key building block for designing novel therapeutic agents. Its potential applications in creating new drugs with improved efficacy and reduced side effects are being explored through ongoing research.
Used in Pharmaceutical Industry:
(S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate is used as a precursor in the synthesis of pharmaceutical compounds for various therapeutic areas. Its versatility and reactivity contribute to the development of innovative medications with enhanced pharmacological profiles.
Used in Research and Development:
(S)-tert-butyl 3-(piperazin-1-yl) pyrrolidine-1-carboxylate is employed as a research tool in academic and industrial laboratories. It aids scientists in understanding the structure-activity relationships of various drug candidates and contributes to the advancement of medicinal chemistry knowledge.

Upstream product

• 717927-56-5 tert-butyl (S)-3-(4-benzylpiperazin-1-yl)pyrrolidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE

The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.

SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS

This invention concerns substituted I-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NK2 and NK3 receptors, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykinin-mediated conditions, such as, for instance CNS disorders, in particular schizoaffective disorders, depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions ; inflammation ; allergic disorders ; emesis ; gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders ; vasospastic diseases ; fibrosing and collagen diseases ; disorders related to immune enhancement or suppression and rheumatic diseases and body weight control.